Search results
5 days ago · Ideally, ascites is medically managed with loop diuretics and mineralocorticoid receptor antagonists, but sometimes, transjugular intrahepatic portosystemic shunt (TIPS) may be necessary to control ascites (though there are insufficient data to recommend TIPS to decrease operative risk).
3 days ago · Cook Medical sponsored a Webcast discussion between specialists in interventional radiology and hepatology on the need for early transjugular intrahepatic portosystemic shunt (TIPS) procedures in patients who suffer from portal hypertension.
3 days ago · A TIPS catheter is a medical device inserted to create a shunt between the portal and hepatic veins to relieve portal hypertension. 2. What are the common uses of TIPS catheters? TIPS catheters are commonly used in patients with complications of portal hypertension, such as variceal bleeding or ascites. 3.
4 days ago · From the view of clinical practice, preoperative awareness of portal venous configuration is important before portal vein embolization, hepatic segments resection, graft procurement in liver transplantation and placement of transjugular intrahepatic portosystemic shunts (TIPS).
5 days ago · The very first model used was the Child–Turcotte–Pugh (CTP) score, developed in 1964 primarily to predict survival in patients undergoing TIPS (transjugular intrahepatic portosystemic shunt) for variceal hemorrhage (Child & Turcotte, 1964; Pugh et al., 1973). CTP is based on five physiological variables, that is, ascites, hepatic ...
3 days ago · Cook Medical sponsored a webcast discussion between specialists in interventional radiology and hepatology on the need for early transjugular intrahepatic portosystemic shunt (TIPS) procedures in patients who suffer from portal hypertension.
4 days ago · Expert opinion . Monitoring for signs of portal hypertension is required. Limited evidence supports ursodeoxycholic acid (UDCA) efficacy in halting CF liver disease progression, while the effect of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on liver outcomes lacks definitive data, since patients with CF-related liver disease were excluded from trials addressing their ...
